Serum levels of 14-3-3η protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis by unknown
RESEARCH ARTICLE Open Access
Serum levels of 14-3-3η protein
supplement C-reactive protein and
rheumatoid arthritis-associated antibodies
to predict clinical and radiographic
outcomes in a prospective cohort of
patients with recent-onset inflammatory
polyarthritis
Nathalie Carrier1, Anthony Marotta2, Artur J. de Brum-Fernandes1,3, Patrick Liang1,3, Ariel Masetto1,3,
Henri A. Ménard4, Walter P. Maksymowych5 and Gilles Boire1,3,6*
Abstract
Background: Age, C-Reactive Protein (CRP) and autoantibodies (Abs) are associated with worse prognosis in
patients with recent-onset inflammatory polyarthritis (EPA). Serum 14-3-3η protein is a joint-derived biomarker that
up-regulates cytokines and enzymes that perpetuate local and systemic inflammation and may contribute to joint
damage. Our objective was to evaluate, over a 5-year prospective period of observation, the additional prognostic
potential of serum 14-3-3η protein in EPA patients.
Methods: Clinical variables, serum and radiographs (scored according to the Sharp/van der Heijde (SvH) method)
were collected serially. Relationships between serum 14-3-3η protein and other biomarkers were computed with
Spearman correlations. Outcomes were Simple Disease Activity Index (SDAI) scores and joint damage progression:
ΔSvH for SvH score and ΔErosion for its Erosive component. The additional predictive contribution of 14-3-3η was
defined using generalized estimating equations (GEE) and generalized linear mixed models (GLMM).
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Results: Among 331 patients, baseline 14-3-3η was ≥0.19 and ≥0.50 ng/ml in 153 (46.2 %) and 119 (36.0 %),
respectively; CRP was >8.0 mg/L in 207 (62.5 %), and at least one Ab (Rheumatoid Factor, anti-CCP2 or anti-Sa/
citrullinated vimentin) was positive in 170 (51.5 %). Elevated 14-3-3η levels moderately correlated with positive Abs,
but not with elevated CRP. Baseline 14-3-3η ≥0.19 ng/ml was associated with more radiographic progression over 5
years. The optimal levels of baseline 14-3-3η to predict radiographic progression was defined by ROC curves at 0.50
ng/ml. Levels of 14-3-3η ≥0.50 ng/ml at baseline were associated with lower likelihoods of ever reaching SDAI
remission (RR 0.79 (95 % CI 0.64–0.98), p = 0.03) and higher subsequent progression of Total and Erosion SvH scores.
Elevated levels of 14-3-3η during follow-up also predicted higher subsequent progression, even in patients in SDAI
remission. Decreases of 14-3-3η levels by at least 0.76 ng/ml and reversion to negative during follow-up associated
with less subsequent radiographic progression. In multivariate models, elevated 14-3-3η interacted with positive
Abs, elevated CRP and older age to predict subsequent radiographic progression.
Conclusions: Levels of 14-3-3η protein ≥0.50 ng/ml predict poorer clinical and radiographic outcomes in EPA, both
at baseline and after initiation of treatment, even in SDAI remitters. 14-3-3η, CRP, age and Abs represent independent
predictors of subsequent joint damage.
Trial registration: ClinicalTrials.gov ID: NCT00512239. Registered August 6, 2007.
Keywords: Recent-onset inflammatory arthritis, 14-3-3η, Radiographic progression, Anti-CCP2 antibodies, Anti-Sa/
citrullinated vimentin antibodies, Rheumatoid factor, CRP, SDAI remission
Background
Rheumatoid arthritis (RA) is the most prevalent chronic
inflammatory joint disease [1]. Despite recent advances in
treatment, RA remains a significant cause of morbidity,
invalidity and premature mortality [2]. The concept of
treat-to-target (T2T) strategies tailored to individual
patients defines specific clinical targets for disease ac-
tivity (e.g., remission or at least low disease activity), re-
duction of C-reactive protein (CRP) and/or erythrocyte
sedimentation rate (ESR) to normal values and the halt-
ing of joint damage within a reasonable time frame.
T2T approaches are particularly effective in early dis-
ease to prevent joint destruction and increase the likeli-
hood of achieving remission, giving rise to the concept
of a ‘window of opportunity’ [2]. One of the limitations
to this approach is the inability of currently available
biomarkers to identify many RA patients early with
recent-onset polyarthritis (EPA), such that early referral
by primary care and effective triaging by joint special-
ists remains incomplete [3]. A second limitation resides
in the inability of the same biomarkers to determine
the expected outcomes at the individual level, which
would allow immediate adjustment of treatment selec-
tion and intensity to the severity of the disease [4].
The 14-3-3 family of conserved regulatory proteins
consists of seven isoforms: α/β, γ, δ/ζ, ε, η, θ/τ and σ
[5]. These proteins normally exist as ubiquitous intra-
cellular adapters (or chaperones) that interact with
over 200 intracellular proteins and contribute to the
modulation of their activities. 14-3-3η is detectable at
significantly higher levels in the serum and synovial
fluid from patients with RA when compared with
healthy subjects and individuals with other auto-
immune conditions and viral/bacterial infections [6].
Extracellular 14-3-3η at concentrations detectable in
RA patient serum acts as a cell damage signal that po-
tently induces pro-inflammatory cytokines and bone-
degrading enzymes [7].
We report the use of serial measurements of serum
14-3-3η protein to evaluate its additive role as a diag-
nostic aid in early disease and as a predictive biomarker
for more severe outcomes of RA at the clinical and
radiographic levels. We also evaluated its additive prog-
nostic potential in combination with established bio-
markers in clinical use, such as CRP and RA-associated
autoantibodies.
Methods
Early undifferentiated polyarthritis (EUPA) patient cohort
The longitudinal EUPA cohort was previously described
[8–10]. Starting in 1998, consecutive adult patients with at
least three swollen joints for one to twelve months were
evaluated at the Centre hospitalier universitaire de Sher-
brooke (CHUS) and asked to participate. We excluded pa-
tients with bacterial or crystal-induced arthritis or a
defined connective tissue disease or systemic vasculitis
according to American College of Rheumatology (ACR)
criteria [11]. Patients were treated by rheumatologists using
early and intensive treatment with dosage individualized to
achieve sustained remission defined as 0 swollen joints out
of 66 joints [2, 12]. Serum samples were coded and stored
at –20 °C. The Ethics Review Board of the CHUS approved
the study (ClinicalTrials.gov ID: NCT00512239) and all
patients provided written informed consent.
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Disease variables
A rheumatologist completed joint counts and a trained
coordinator conducted a structured interview at inclusion
and at each of the follow-up visits scheduled at 18, 30, 42
and 60 months after onset. Time of onset was self-reported
as the week during which symptoms/signs of inflammatory
arthropathy had appeared. Variables assessed included
demographics; 68 tender joint count (TJC) and 66 swollen
joint count (SJC); drug use at and between each visit;
modified Health Assessment Questionnaire (M-HAQ)
[13]; serum CRP (upper normal limit: 8.0 mg/L); compo-
nents of the Simplified Disease Activity Index (SDAI); and
RA-associated antibodies (see below). Radiographs of the
hands and feet were obtained at inclusion and at each
scheduled assessment. Joint space narrowing and erosions
were scored on these radiographs according to the
Sharp score modified by van der Heijde (SvH) method,
with a maximum score of 448 units [14]. Radiographs
were read in known time sequence by two blinded as-
sessors, one of which was a study investigator (GB).
Under these conditions, the smallest detectable change
(SDC) was 5 units [15].
RA-associated antibodies
IgM rheumatoid factor (RF) was measured using RapiTex
RF (Dade Behring Inc, Newark DE, USA) (positive
≥40 IU/ml). Anti-CCP2 antibodies were measured using
QuantaLite™, Inova Diagnostics (San Diego, CA, USA)
using titer levels as suggested by the manufacturer
(positive >20.0 U/ml) or, since 2009, using the Euro-
Immun assay (positive >5.0 U/ml). As both the EuroIm-
mun and the Inova assays use the same enzyme linked
immunosorbent assay (ELISA) plates coated with the
same antigens (as do all other antibodies to cyclic citrulli-
nated peptide, second generation (anti-CCP2) assays
across the world), have similar sensitivity and specificity,
and give linear results across a wide range of concentra-
tions, their results are easily interconvertible using the
following logarithmic transformation:
Inova anti-CCP2 = –26.44 + 28.86 * ln(EuroImmun anti-
CCP2).
The anti-Sa/citrullinated vimentin in-house ELISA was
described previously (positive threshold ≥0.20 optical
density units) [16]. From 2012 on, we used a commercial
anti-Sa assay (EuroImmun; positive >19 RU/ml), vali-
dated against our in-house ELISA [17].
Outcomes
Radiographic progression was defined by the differ-
ence between the SvH scores over time and baseline
damage. Definite SvH progression was defined as an
increase ≥5 in either the total score (ΔSvH) or its
erosion component (ΔErosion). Remission was defined
as SDAI ≤3.3 [18].
Serum 14-3-3η measurements
Serum 14-3-3η levels were measured using the 14-3-3η
ELISA according to the manufacturer’s protocol
(Augurex Life Sciences Corp, Vancouver, BC, Canada).
Samples with levels below the reportable range were
assigned a concentration of 0.0 ng/ml and those with
levels above the upper limit were defined as having
levels ≥20 ng/ml. Positivity for 14-3-3η was defined by
the manufacturer at ≥0.19 ng/ml.
Statistical methods
Quantitative variables were presented as mean (standard
deviation (SD)) or as the median and 25th–75th percentiles
(interquartile range (IQR)). Categorical variables were pre-
sented with frequencies and percentages. 14-3-3η levels at
each visit were compared to baseline levels using the
Wilcoxon sign rank test. SDAI scores and remission status,
SvH score, ΔSvH and ΔErosion were compared with base-
line 14-3-3η positivity using the Mann–Whitney U test, in-
dependent samples Student t test and Pearson’s chi-square
test, as appropriate. To evaluate the benefit of using positive
14-3-3η protein to support RA diagnosis among EPA pa-
tients, we combined elevated 14-3-3η levels with positive
RA-associated antibodies. The incremental benefit of posi-
tive 14-3-3η over single types of antibody or combinations
of antibodies was calculated as the patients identified by a
positive 14-3-3η result among patients negative for the bio-
marker of reference, divided by the number of patients
positive for the biomarker of reference. The significance of
the observed incremental benefit was evaluated using the
McNemar test. Receiver operator characteristic (ROC)
curves were used to establish the optimal threshold of base-
line 14-3-3η positivity for prediction of ΔSvH ≥5 from in-
clusion to 5 years. Spearman correlation was used to
evaluate association between baseline variables. Generalized
linear mixed (GLMM) models with repeated measures
were used to evaluate effect of baseline 14-3-3η positivity
on SDAI, SvH score, ΔSvH and ΔErosion over time. Gener-
alized estimating equations (GEE) for binary outcomes with
repeated measures were used to measure relative risk (RR)
of attaining SDAI remission, ΔSvH ≥5, ΔErosion ≥5 and
use of biologic DMARDs over time according to 14-3-3η
positivity at inclusion or at the previous visit. Multivariate
GLMM and GEE models were computed to evaluate which
baseline variables explained progression of SvH score over
time. Age, gender, 14-3-3η, antibodies and CRP were ana-
lyzed as continuous or categorical variables. In analyses
with repeated measures, the covariance structure (auto-
regressive, compound symmetry, variance components or
unstructured) with the lowest Akaike information criteria
(AIC) for GLMM or quasi-AIC (QIC) for GEE was used to
model the subject variation. All variables and interaction
terms were included in the first model. We then deleted
one by one the variables or interaction terms that were not
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significant; when deletion of a variable or interaction term
resulted in an increase rather than a decrease in the AIC or
QIC, this variable or interaction term was kept in the
model. This process continued until we reached the smal-
lest AIC or QIC. All analyses were based only on available
data without imputation, as fewer than 5 % of values for
each variable were missing. Statistical analysis was per-
formed using SAS software version 9.3, SPSS software ver-
sion 23.0 and GraphPad Prism Software version 6.00 for
Windows. A p value <0.05 denoted statistical significance.
Results
Elevated 14-3-3η serum protein levels at baseline and
over time
As of 15 May 2014, from the 688 included in the on-
going EUPA cohort, 331 patients (62 % women, mean
age 60 years) had completed 5 years of follow up and
were selected for this study (Table 1). Median symptom
duration at baseline was 3 months, and over 92 %
already fulfilled either the 1987 ACR or the 2010 ACR/
EULAR classification criteria for RA. We previously re-
ported that not meeting the 1987 ACR criteria for RA
at baseline did not significantly impact subsequent out-
comes in our patients [10, 16]. Disease activity was
moderate to high: median (IQR) SDAI 30.1 (19.8–45.2);
median M-HAQ (IQR) 0.8 (0.4-1.4). Baseline joint
damage was low, with median total SvH (IQR) of 2 (0–6)
and median erosion SvH (IQR) of 1 (0–3). Patients rapidly
received DMARDs, usually methotrexate (MTX), alone or
in combination with other DMARDs [8–10, 16].
Baseline levels of 14-3-3η protein were ≥0.19 ng/ml
(threshold suggested by the manufacturer) in 153 patients
(46.2 %) and ≥0.50 ng/ml (the optimal prognostic threshold
defined in our cohort; see below) in 119 patients (36.0 %).
CRP was >8.0 mg/ml in 207 patients (62.5 %), and RF,
anti-CCP2 and anti-Sa antibodies (Abs) were positive in
Table 1 Baseline cohort characteristics
Variable Number Value
Age, median (IQRa), years 331 60 (49.4–68.6)
Age ≥65 years, n (%) 331 122 (36.9)
Women, n (%) 331 205 (61.9)
Current smoker, n (%) 330 69 (20.9)
Symptom duration, median (IQR), months 331 3.1 (1.7–5.7)
Body mass index, median (IQR), kg/m2 309 26.1 (23–29.8)
25–29.9, n (%) 104 (33.7)
≥30, n (%) 74 (23.9)
Swollen joint count, 28 joints, median (IQR) 330 9 (5–15)
Tender joint count, 28 joints, median (IQR) 329 9 (4–16)
Fulfilling 1987 ACR criteria for rheumatoid arthritis, n (%) 331 275 (83.1)
Fulfilling 2010 EULAR/ACR criteria for rheumatoid arthritis, n (%) 330 281 (85.2)
Fulfilling 1987 or 2010 sets of criteria for rheumatoid arthritis, n (%) 330 304 (92.1)
Disease Activity Score, 28 joints-C-reactive protein, median (IQR) 328 5.1 (4.2–6.2)
Simplified Disease Activity Index, median (IQR) 328 30.1 (19.8–45.2)
Modified Health Assessment Questionnaire, median (IQR) 329 0.8 (0.4–1.4)
Total SvH score, median (IQR) 328 2 (0–6)
SvH erosion score, median (IQR) 328 1 (0–3)
Erythrocyte sedimentation rate, mm/h, median (IQR) 331 33 (17–46)
C-reactive protein, mg/L, median (IQR) 331 13.1 (4.5–32.0)
C-reactive protein >8.0 mg/L 331 207 (62.5)
Rheumatoid factor-positive, ≥40 IU/ml 331 146 (44.1)
Anti-CCP2 positive 331 133 (40.2)
Anti-Sa positive 331 73 (22.1)
14-3-3η, ng/ml, median (IQR) 331 0.1 (0.0–1.9)
14-3-3η positive, ≥0.19 ng/ml 331 153 (46.2)
14-3-3η positive, ≥0.50 ng/ml 331 119 (36.0)
aIQR 25th–75th percentiles. ACR American College of Rheumatology. EULAR European League Against Rheumatism, Anti-CCP2 antibodies to citrullinated peptides,
second generation. SvH Sharp score modified by van der Heijde
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146 (44.1 %), 133 (40.2 %) and 73 (22.1 %) of patients,
respectively; 170 patients (51.5 %) had at least one positive
antibody.
Median (IQR) 14-3-3η levels significantly decreased
between baseline (0.14 (0.03–1.86) ng/ml) and each
follow-up measurement: 0.11 (0.03–1.12), p <0.0001; 0.11
(0.03–0.99), p <0.0001; 0.10 (0.02–0.93), p <0.0001; and
0.13 (0.02–1.14) ng/ml, p = 0.001 at 18, 30, 42 and 60
months, respectively (Additional file 1). The mean
(+/- SD) decrease in 14-3-3η titers between baseline
and subsequent visits was 0.72 (5.20), 0.62 (5.98), 0.86
(5.54) and 0.58 (6.11) ng/ml at 18, 30, 42 and 60 months,
respectively. As a consequence, the proportion of patients
remaining 14-3-3η-positive among those with baseline
levels ≥0.50 ng/ml dropped to 70 % and 75 % at 42 and 60
months, respectively (Additional file 1). On the contrary,
90–95 % of the patients with baseline 14-3-3η <0.50 ng/ml
remained negative over follow up (Additional file 1).
Complementarity of 14-3-3η in identification of patients
with early RA
To assess the potential of 14-3-3η assessment to help
primary care providers consider RA diagnosis in EPA
patients, we combined elevated 14-3-3η levels with posi-
tive RA-associated antibodies. Using the manufacturer’s
suggested positivity cutoff of ≥0.19 ng/ml increased the
number of patients with at least one of the four bio-
markers to 194 (58.8 %), a 14.1 % incremental benefit
(Table 2). Of the 24 additional patients identified by
elevated 14-3-3η, 20 already fulfilled 1987 and/or 2010
criteria for RA at baseline, despite being antibody-negative.
Defining the optimal 14-3-3η threshold to predict worse
radiographic outcomes
The higher the 14-3-3η baseline levels the stronger the
association with radiographic progression between base-
line and each of the follow-up evaluations (r approxi-
mately 0.19, p <0.001). Similarly, the higher the decrease
in 14-3-3η titers between baseline and 18 months, the
lesser the radiographic progression from 18 to 30
months (r = –0.14, p = 0.018); ROC curve analyses de-
fined a decrease of <0.76 ng/ml as the best to predict
definite radiographic progression (ΔSvH ≥5) over 5
years: 28.6 % vs 14.3 %, RR (95 % CI) = 2.00 (1.20–
3.34), p = 0.01 (area under the curve (AUC) = 0.567,
sensitivity = 0.844, specificity = 0.308). The 21 patients
Table 2 Additional contribution of positive 14-3-3η to identify rheumatoid arthritis amongst patients with early inflammatory arthritis
1987+/2010+ 1987+/2010– 1987–/2010+ 1987–/20– Total Incremental benefit










Rheumatoid factor+ 140 (55.6) 0 (0) 6 (20.7) 0 (0) 146 (44.2) NA
Anti-CCP2+ 119 (47.2) 0 (0) 14 (48.3) 0 (0) 133 (40.3) NA
Anti-Sa+ 67 (26.6) 0 (0) 6 (20.7) 0 (0) 73 (22.1) NA
Rheumatoid factor + and/or anti-CCP2+ 153 (60.7) 0 (0) 14 (48.3) 0 (0) 167 (50.6) NA
Rheumatoid factor + and/or anti-CCP2+
and/or anti-Sa+
155 (61.5) 0 (0) 15 (51.7) 0 (0) 170 (51.5) NA
14-3-3η ≥0.19 ng/ml 134 (50.6) 1 (10) 14 (43.8) 4 (17.4) 153 (46.4) NA
14-3-3η ≥0.50 ng/ml 111 (44.0) 0 (0) 8 (27.6) 0 (0) 119 (36.1) NA
14-3-3η≥ 0.19 ng/ml and/or
Rheumatoid factor+ 161 (63.9) 1 (4.3) 15 (51.7) 4 (15.4) 181 (54.8) 24.0 %***
Anti-CCP2+ 158 (62.7) 1 (4.3) 19 (65.5) 4 (15.4) 182 (55.2) 36.8 %***
Anti-Sa+ 144 (57.1) 1 (4.3) 15 (51.7) 4 (15.4) 164 (49.7) 124.7 %***
Rheumatoid factor + and/or anti-CCP2+ 168 (66.7) 1 (4.3) 19 (65.5) 4 (15.4) 192 (58.2) 15.0 %***
Rheumatoid factor + and/or anti-CCP2+
and/or anti-Sa+
170 (64.2) 1 (10) 19 (59.4) 4 (17.4) 194 (58.8) 14.1 %***
14-3-3η≥ 0.50 ng/ml and/or
Rheumatoid factor+ 150 (59.5) 0 (0) 9 (31.0) 0 (0) 159 (48.2) 8.9 %***
Anti-CCP2+ 147 (58.3) 0 (0) 15 (51.7) 0 (0) 162 (49.1) 21.8 %***
Anti-Sa+ 126 (50.0) 0 (0) 11 (37.9) 0 (0) 137 (41.5) 87.7 %***
Rheumatoid factor + and/or anti-CCP2+ 159 (63.1) 0 (0) 15 (51.7) 0 (0) 174 (52.7) 4.2 %**
Rheumatoid factor + and/or anti-CCP2+
and/or anti-Sa+
161 (63.9) 0 (0) 16 (55.2) 0 (0) 177 (53.6) 4.1 %**
aData insufficient to assess 2010 American College of Rheumatology/European League Against Rheumatism criteria in one patient; **p <0.01; ***p <0.001. Anti
CCP2 antibodies to citrullinated peptides, second generation. NANot applicable
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whose 14-3-3η status reverted from ≥0.19 at baseline to
negative by 18 months had lower median (IQR) base-
line titers: 0.3 (0.3–0.6) versus 3.6 (1.0–21.0) ng/ml in
those who remained positive. As low or transiently
positive titers of a biomarker are usually less specific
and have weaker associations with specific outcomes,
ROC curves were drawn to define the optimal level of
baseline 14-3-3η to predict radiographic outcomes.
Using two thresholds for ΔSvH or ΔErosion (3 or 5
units) and the shortest length of observation (3 years),
the optimal level of baseline 14-3-3η was 0.490 ng/ml
(ROC curves not shown). As no patient had values be-
tween 0.490 and 0.500, we therefore selected 0.50 ng/
ml as the optimal prognostic threshold for 14-3-3η.
The threshold of 0.50 ng/ml at baseline was associated
with more erosive progression (ΔErosion ≥5) over 5
years (GEE: RR (95 % CI) = 2.01 (1.49-2.72), p <0.001)
compared to levels <0.19 ng/ml (Table 3). The 31
patients with baseline 14-3-3η levels between 0.19
and 0.49 ng/ml and the 169 patients with levels
<0.19 ng/ml had similar risk for total SvH and erosion
progression (Table 3). Compared to those with 14-3-3η
≥0.19 but <0.50 ng/ml, patients with levels ≥0.50 ng/ml
had higher risk of definite radiographic progression
(ΔSvH ≥5; RR 1.82 (1.11–3.00), p <0.05) and erosive
progression (ΔErosion ≥5; RR 2.15 (1.21–3.83), p <0.01). As
a consequence, a threshold for positivity of ≥0.50 ng/ml
was selected for presentation in this report. Results of
some analyses using a threshold of ≥0.19 ng/ml are
shown in Additional file 2.
Baseline 14-3-3η serum protein levels identify patients
with refractory disease over 5 years
At baseline, median SDAI, DAS28-CRP, and total and
erosion SvH levels were not significantly different based
on positive or negative 14-3-3η levels ≥0.50 ng/ml; simi-
lar results were obtained with a threshold ≥0.19 (data
not shown). When patients were grouped according to
14-3-3η-positive status at baseline, GLM analysis revealed
that SDAI scores were significantly higher (p = 0.002)
across all visits in 14-3-3η-positive patients at baseline
(data not shown). GEE analysis revealed that fewer pa-
tients achieved SDAI remission based on a baseline 14-3-
3η ≥0.50, delivering a relative risk (RR) of 0.79 (95 % CI
0.64–0.98), p = 0.03 (Fig. 1a); similar results were obtained
with the 0.19 ng/ml threshold (Additional file 2A). Not
surprisingly, baseline 14-3-3η ≥0.50 ng/ml was also as-
sociated with an increased risk of definite radiographic
progression (ΔSvH ≥5; RR =1.60 (95 % CI 1.28–2.00),
p <0.001; ΔErosion ≥5; RR =2.04 (95 % CI 1.53–2.70),
p <0.001 (Fig. 1b), and a trend for use of biologic
DMARDs over time (RR =1.62 (0.94–2.80), p = 0.085).
Baseline 14-3-3η ≥0.19 ng/ml was associated with a
lower risk for definite radiographic progression (ΔSvH
≥5; RR =1.39 (95 % CI 1.11–1.74), p = 0.005 (Additional
file 2B). As a consequence, patients with baseline 14-3-3η
≥0.50 ng/ml had higher mean radiographic progression at
60 months (mean ± SD for ΔSvH: 13.08 ± 17.34 vs 7.30 ±
13.38, p = 0.002 and ΔErosion: 9.23 ± 13.22 vs 4.37 ± 9.05,
p = 0.001).
Elevated 14-3-3η protein levels during follow up predict
more rapid radiographic progression over the following
years, even in patients in SDAI remission
Only 308/331 patients had a full series of baseline, 18-
month and 30-month radiographs; the 23 without either
18-month or 30-month radiographs had similar 14-3-3η
levels at baseline and at 30 months. Of the 308 patients
with complete radiographs, 84 (27.3 %) were 14-3-3η-
positive (≥0.50) at both baseline and 18-month visits,
and 23 patients (7.5 %), who were positive at baseline,
reverted to negative and 11 patients (3.6 %), who were
initially negative converted to positive at 18 months.
The 23 patients who sero-reverted from positive 14-3-3η
to negative at 18 months had mild progression between
18 and 30 months, similar to the 190 persistently nega-
tive patients (1.77 ± 3.83 vs 2.74 ± 3.02, p = 0.243). On
the contrary, patients who were 14-3-3η-positive at 18
months developed significantly higher ΔSvH over the
following years, both in those with active disease as
assessed by the SDAI at 18 months and to a lesser
extent, in patients in SDAI remission at 18 months
(Fig. 2a). Radiographic progression slowed but persisted
after the 30-month visit, despite a gradual increase in
use of biologic DMARDs (6.4 %, 11.6 %, 13.8 % and 14.8
% at 18, 30, 42 and 60 months, respectively) and in the
prevalence of SDAI remission (Fig. 1a). Nonetheless,
14-3-3η ≥0.50 ng/ml at each visit correlated with more
rapid progression over the following years, even in
those who were in SDAI remission at the same visit
(Fig. 2b).
Elevated 14-3-3η serum levels improve outcome prediction
associated with positive RA-associated antibodies, CRP and
older age
Before increasing the range of available biomarkers
used for outcome prediction in RA, we need to esti-
mate the additional information contributed by 14-3-3η
detection. Table 4 presents the Spearman correlation
between baseline variables. As expected, antibodies cor-
related moderately/strongly with each other. Interest-
ingly, positive antibodies and 14-3-3η ≥0.50 ng/ml were
also moderately correlated (r = 0.679 for RF, 0.539 for
anti-CCP2 and 0.437 for anti-Sa). Age was moderately
correlated with SvH scores, and 14-3-3η levels nega-
tively correlated weakly with age (r = -0.140, p = 0.01).
Levels of CRP and 14-3-3η did not correlate (Spearman
correlation r =0.001; p = 0.996) (Table 4).
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Table 3 Impact of biomarkers on radiographic and erosive progression (ΔSvH ≥5 and ΔErosion ≥5)
ΔSvH ≥ 5 ΔErosion ≥ 5
Baseline variables Total, number at 60 m,
number (%)




RR (95 % CI) from
GEE over time
14-3-3η, ng/ml
<0.19 169 73 (43.2) 1 48 (28.4) 1
0.19–0.50 31 12 (38.7) 0.86 (0.52–1.43) 10 (32.3) 0.93 (0.51–1.70)
≥0.50 115 74 (64.3) 1.57 (1.24–1.97) *** 60 (52.2) 2.01 (1.49–2.72) ***
14-3-3η, ng/ml
<0.19 169 73 (43.2) 1 48 (28.4) 1
≥0.19 146 86 (58.9) 1.40 (1.11–1.77) ** 70 (47.9) 1.77 (1.31–2.38) ***
14-3-3η, ng/ml
<0.50 200 85 (42.5) 1 58 (29.0) 1
≥0.50 115 74 (64.3) 1.60 (1.28–2.00) *** 60 (52.2) 2.04 (1.53–2.70) ***
Age, years
<65 198 81 (40.9) 1 62 (31.3) 1
≥65 117 78 (66.7) 1.71 (1.36–2.13) *** 56 (47.9) 1.51 (1.13–2.01) **
C-reactive protein, mg/L
≤8.0 117 51 (43.6) 1 30 (25.6) 1
>8.0 198 108 (54.5) 1.46 (1.12–1.90) ** 88 (44.4) 1.87 (1.31–2.66) ***
Anti-CCP2 status
Negative 190 85 (44.7) 1 59 (31.1) 1
Positive 125 74 (59.2) 1.44 (1.14–1.80) ** 59 (47.2) 1.74 (1.31–2.33) ***
RF ≥40 IU/ml
Negative 176 76 (43.2) 1 51 (29.0) 1
Positive 139 83 (59.7) 1.51 (1.20–1.90) *** 67 (48.2) 2.02 (1.50–2.72) ***
Anti-Sa status
Negative 246 110 (44.7) 1 76 (30.9) 1
Positive 69 49 (71.0) 1.72 (1.38–2.14) *** 42 (60.9) 2.22 (1.69–2.92) ***
RF or anti-CCP2 positive
Negative 157 67 (42.7) 1 44 (28.0) 1
Positive 158 92 (58.2) 1.53 (1.21–1.94) *** 74 (46.8) 2.02 (1.47–2.76) ***
14-3-3η ≥0.50 ng/ml and age ≥65 years
Both negative 117 34 (29.1) 1 24 (20.5) 1
One positive 164 98 (59.8) 2.35 (1.71–3.23) *** 72 (43.9) 2.40 (1.61–3.57) ***
Both positive 34 27 (79.4) 2.96 (2.07–4.24) *** 22 (64.7) 3.46 (2.21–5.42) ***
14-3-3η ≥0.50 and C-reactive protein >8.0 mg/L
Both negative 73 28 (38.4) 1 16 (21.9) 1
One positive 171 80 (46.8) 1.25 (0.88–1.76) 56 (32.7) 1.58 (0.97–2.58)
Both positive 71 51 (71.8) 2.21 (1.58–3.09) *** 46 (64.8) 3.48 (2.17–5.56) ***
14-3-3η ≥0.50 ng/ml and anti-CCP2
Both negative 163 68 (41.7) 1 45 (27.6) 1
One positive 64 34 (53.1) 1.4 (1.04–1.89) * 27 (42.2) 1.74 (1.19–2.54) **
Both positive 88 57 (64.8) 1.7 (1.32–2.20) *** 46 (52.3) 2.27 (1.62–3.16) ***
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Univariate analyses of single biomarkers and their
combinations were evaluated in relation to total and
erosive joint damage progression over 5 years of disease
(Table 3). Definite progression of total (ΔSvH ≥5) and
erosive joint damage (ΔErosion ≥5) were associated in
univariate analyses with the following baseline vari-
ables: CRP >8.0 mg/L, age ≥65 years, positive anti-Sa,
positive RF, positive anti-CCP2 and 14-3-3η ≥0.50, with
the RR ranging from 1.51–2.22 (Table 3). Relative to
erosive progression, a slightly weaker RR for total SvH
progression was observed with all variables, with the
exception that age ≥65 years was more strongly associ-
ated with total than erosive progression. Coexistence of
both 14-3-3η ≥0.50 and CRP >8.0 increased the RR of
erosive progression ≥5 to 3.48 (2.17–5.56), p <0.001
relative to the absence of both; combining 14-3-3η
≥0.50 with age ≥65 years increased the RR of erosive
progression to 3.46 (2.21–5.42), p <0.001. Combining
14-3-3η ≥0.50 with either positive RF, anti-CCP2 or anti-
Sa did not markedly improve the RR for erosive pro-
gression associated with antibodies (2.27, 2.32 and
2.80, respectively). The optimal univariate combined
predictor for erosive progression ≥5 was obtained
using a combination of CRP >8.0 mg/L and 14-3-3η
≥0.50 ng/ml and age ≥65 years, with a RR of 5.49
(2.73–11.08) compared to the absence of all three vari-
ables (Table 3).
Multivariate predictive models using continuous and
dichotomous baseline biomarkers and their significant
interactions were also evaluated in relation to definite
total and erosive damage progression over 5 years of dis-
ease (Table 5). Multivariate GLM analysis with repeated
measures of continuous variables showed that baseline
age, CRP levels, positive anti-Sa status and 14-3-3η levels
were the independent variables significantly associated
with both ΔSvH ≥5 and ΔErosion ≥5 over time. In
multivariate GEE analysis with repeated measures using
dichotomous variables and their interactions, age ≥65
years, CRP >8.0 mg/L and 14-3-3η ≥0.50 ng/ml were the
independent predictors of ΔSvH ≥5; age ≥65 years, CRP
>8.0 mg/L and 14-3-3η ≥0.50 were again the significant
predictors of erosive progression ≥5, together with anti-
Sa and RF positivity, and the interaction of 14-3-3η
≥0.50 with antibody positivity (Table 5).
Discussion
We show that serum 14-3-3η protein levels can be used
in addition to baseline RA-associated antibodies to facili-
tate early identification among EPA patients, of those
RA patients likely to have poor outcomes, both clinically
Table 3 Impact of biomarkers on radiographic and erosive progression (ΔSvH ≥5 and ΔErosion ≥5) (Continued)
14-3-3η ≥0.50 ng/ml and RF
Both negative 165 69 (41.8) 1 44 (26.7) 1
One positive 46 23 (50.0) 1.31 (0.93–1.86) 21 (45.7) 1.80 (1.19–2.72) **
Both positive 104 67 (64.4) 1.68 (1.32–2.15) *** 53 (51.0) 2.32 (1.67–3.22) ***
14-3-3η≥ 0.50 ng/ml and anti-Sa
Both negative 185 75 (40.5) 1 51 (27.6) 1
One positive 76 45 (59.2) 1.36 (1.03–1.79) * 32 (42.1) 1.64 (1.15–2.34) **
Both positive 54 39 (72.2) 2.02 (1.57–2.59) *** 35 (64.8) 2.80 (2.04–3.85) ***
14-3-3η≥ 0.50, “RF and/or anti-CCP2”
Both negative 152 64 (42.1) 1 41 (27) 1
One positive 110 71 (64.5) 1.23 (0.87–1.74) 57 (51.8) 1.59 (1.04–2.44) *
Both positive 53 24 (45.3) 1.71 (1.33–2.19) *** 20 (37.7) 2.34 (1.67–3.27) ***
14-3-3η≥ 0.50, Age ≥65, C-reactive protein >8.0
All negative 43 11 (25.6) 1 7 (16.3) 1
Only C-reactive protein positive 74 23 (31.1) 1.25 (0.67–2.32) 17 (23.0) 1.54 (0.71–3.36)
Only 14-3-3η positive 34 16 (47.1) 1.87 (0.97–3.60) 10 (29.4) 2.18 (0.94–5.06)
Only age positive 30 17 (56.7) 2.41 (1.31–4.43) ** 9 (30.0) 2.06 (0.86–4.89)
Only C-reactive protein and age positive 53 34 (64.2) 2.97 (1.71–5.18) *** 25 (47.2) 3.27 (1.59–6.71) **
Only 14-3-3η and C-reactive protein- positive 47 31 (66.0) 3.21 (1.85–5.59) *** 28 (59.6) 4.65 (2.33–9.29) ***
Only 14-3-3η and age-positive 10 7 (70.0) 2.22 (1.02–4.84) * 4 (40.0) 2.47 (0.85–7.17)
All positive 24 20 (83.3) 3.90 (2.25–6.78) *** 18 (75.0) 5.49 (2.73–11.08) ***
*p <0.05, **p <0.01, ***p <0.001. ΔSvH progression in the total Sharp score modified by van der Heijde, ΔErosion progression in the erosion component of the
Sharp score modified by van der Heijde, GEE general estimating equation, RF rheumatoid factor, Anti-CCP2 antibodies to citrullinated peptides, second generation
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and radiographically. 14-3-3η-positive status can thus
assist primary care providers during referral of patients
to rheumatologists, and may help rapid initiation of a
targeted pharmacological intervention. Furthermore, our
results show that elevated levels of 14-3-3η can be used
in combination with known prognostic biomarkers to
identify patients with the worst prognosis for radio-
graphic progression, both initially in untreated patients
Fig. 1 Simplified Disease Activity Index (SDAI) remission (a) and erosive progression (b) over 5 years according to baseline 14-3-3η positivity. General
estimating equations analysis was performed to compare SDAI scores and radiographic progression over time with baseline 14-3-3η ≥0.50 ng/ml.
a SDAI remission over time was significantly lower in patients with baseline 14-3-3η ≥0.50 (relative risk (RR) = 0.79 (95 % CI 0.64–0.98),
p = 0.03). b Definite erosive progression (ΔErosion ≥5) over time was significantly higher in patients with baseline 14-3-3η ≥0.50 ng/ml
(RR = 2.04 (95 % CI 1.53–2.70), p <0.001)
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and in patients already under treatment. A higher level
of baseline 14-3-3η (≥0.50 ng/ml) appears superior to
the manufacturer-recommended threshold of 0.19 ng/ml
to identify those patients most likely to progress rapidly,
potentially mandating earlier and more specific antirheu-
matic strategies.
Fig. 2 Radiographic progression over 5 years according to Simplified Disease Activity Index (SDAI) remission and 14-3-3η positivity. Generalized
linear model analysis was performed to compare radiographic progression over time with 14-3-3η ≥0.50 ng/ml. a Relative to patients with lower
14-3-3η levels, erosive damage progression (ΔErosion) was significantly higher in patients with 14-3-3η ≥0.50 ng/ml at 18 months, whether the
patients were in SDAI remission (p = 0.002) or had active SDAI levels at 18 months (p <0.001). b Relative to patients with lower 14-3-3η levels,
yearly erosive damage progression (ΔErosion) was significantly higher in patients with 14-3-3η ≥0.50 ng/ml at the previous visit, whether the
patients were already in SDAI remission (p = 0.0079) or had active SDAI levels (p <0.001) at the previous visit. SEM standard error of the mean
Carrier et al. Arthritis Research & Therapy  (2016) 18:37 Page 10 of 14
14-3-3η protein presents mechanistic potential distinct
from those of other known RA biomarkers. 14-3-3η is
found at increased concentrations in the serum of RA
patients, and even more so in their synovial fluid. In vitro
and ex vivo, extracellular 14-3-3η acts as a ligand that
increases production of inflammatory mediators such as
interleukin 6 (IL-6) and tumor necrosis factor α (TNFα),
and osteoclast-activating factors such as receptor activa-
tor of nuclear factor kappa-B ligand (RANKL). Similar to
high or sustained levels of elevated CRP, high baseline
and persistently high levels of 14-3-3η are associated with
a worse prognosis. Inflammation and joint damage,
which are now understood to be processes that uncouple
along the course of disease and treatment strategies, have
been tightened to achieve both clinical and joint damage
remission. CRP and 14-3-3η are both associated with
joint damage progression at 5 years and their respective
titers are not correlated, consistent with distinct roles in
RA disease processes [19]. Surprisingly, combining
elevated 14-3-3η with RA-associated antibodies did not
markedly improve the RR for radiographic progression
found with elevated 14-3-3η or antibodies alone. Positive
RF presents similarly high correlations with both elevated
14-3-3η protein (r =0.679) and positive anti-CCP2
(r =0.661). This does not result from a spurious effect of
RF on the performance of the 14-3-3η ELISA assay itself
[19]. We postulate that extracellular 14-3-3η may
stimulate B cells, potentially leading to or stimulating the
production of RA-associated antibodies; further investi-
gation is needed to answer this question. As CRP,
RA-associated antibodies and 14-3-3η protein represent
modifiable joint damage mechanism markers with very
distinct amplitude and kinetics of response to specific
treatments, the complementary information provided by
Table 4 Spearman correlation (ρ) between baseline continuous and categorical variables
Baseline variables 14-3-3η 14-3-3η 14-3-3η Anti-CCP2 Anti-CCP2-
positive
RF RF positive Age (years) Age ≥65 years BMI ≥30
≥0.19 ≥0.50
14-3-3η 1
14-3-3η≥ 0.19 0.865 *** 1
14-3-3η≥ 0.50 0.833 *** 0.808 *** 1
Anti-CCP2 0.529 *** 0.515 *** 0.530 *** 1
Anti-CCP2-positive 0.529 *** 0.524 *** 0.539 *** 0.849 *** 1
RF 0.716 *** 0.659 *** 0.731 *** 0.624 *** 0.638 *** 1
RF positive 0.669 *** 0.616 *** 0.679 *** 0.616 *** 0.661 *** 0.927 *** 1
Anti-Sa positive 0.409 *** 0.413 *** 0.437 *** 0.527 *** 0.519 *** 0.500 *** 0.481 ***
Age (years) -0.140 * -0.118 * -0.087 -0.033 -0.085 -0.069 -0.104 1
Age ≥65 years -0.151 ** -0.131 * -0.103 -0.040 -0.095 -0.071 -0.099 0.836 *** 1
BMI ≥30 -0.028 0.042 0.007 -0.031 -0.013 -0.014 -0.039 -0.06 -0.024 1
Gender (women vs men) -0.031 -0.034 -0.074 -0.010 -0.033 -0.044 -0.030 -0.158 ** -0.072 0.000
Symptom duration (months) 0.119 * 0.127 * 0.122 * 0.144 0.164 0.146 0.141 -0.067 -0.032 -0.002
Current smoker 0.137 * 0.075 0.110 * -0.022 0.005 0.091 0.112 -0.221 *** -0.206 *** -0.068
M-HAQ 0.024 0.009 0.000 -0.030 -0.064 -0.024 -0.053 0.112 * 0.032 0.138 *
DAS28-CRP 0.061 0.052 0.077 0.023 -0.009 0.064 0.013 0.135 ** 0.101 0.048
SDAI 0.041 0.033 0.067 0.009 -0.024 0.050 -0.006 0.112 ** 0.089 0.02
Pain 0.012 -0.004 -0.011 0.029 0.003 0.051 0.043 0.011 0.014 0.124 *
ESR 0.044 0.059 0.076 0.035 0.007 0.089 0.067 0.267 *** 0.196 *** 0.115 *
CRP 0.000 -0.011 0.023 0.014 0.021 0.015 -0.009 0.151 ** 0.091 0.091
CRP >8 -0.02 -0.021 0.008 0.002 0.008 -0.015 -0.029 0.091 0.048 0.028
SJC28 0.019 0.010 0.055 -0.019 -0.059 0.036 0.000 0.094 0.084 -0.043
TJC28 0.082 0.080 0.103 0.008 -0.022 0.065 0.005 0.124 * 0.102 0.009
Total SvH score 0.036 0.051 0.049 0.009 0.024 0.026 -0.005 0.491 *** 0.391 *** 0.013
SvH erosion score 0.04 0.035 0.052 0.021 0.049 0.050 0.022 0.360 *** 0.287 *** 0.02
*p <0.05, **p <0.01, ***p <0.001. Anti-CCP2 antibodies against citrullinated peptides, second generation, RF rheumatoid factor, BMI body mass index, M-HAQ
Modified Health Assessment Questionnaire, DAS28 Disease Activity Score in 28 joints, SDAI Simplified Disease Activity Score, ESR erythrocyte sedimentation rate,
CRP C-reactive protein, SJC swollen joint count, TJC tender joint count, SvH progression in the total Sharp score modified by van der Heijde
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all three may enhance clinical management strategies
[20]. Univariate and multivariate interaction analyses fur-
ther revealed that combining 14-3-3η and CRP resulted
in better predictors of future radiographic damage than
either marker alone. Concomitant serial testing of the
modifiable CRP and 14-3-3η markers may thus assist
with tight-control RA treatment strategies. As increased
progression persisted in patients who were 14-3-
3η-positive despite being in SDAI remission, innovative
therapies may be needed to further improve the final out-
comes of these patients.
Our results show increasing age as an important pre-
dictor of joint damage progression, especially of joint
space narrowing. The reasons for the detrimental impact
of age are many, including increased susceptibility of
osteoarthritis-damaged cartilage to degradative enzymes
induced by inflammation, the effect of ongoing osteo-
arthritis itself superimposed on that of inflammatory
arthritis, greater susceptibility of aging bone to resorp-
tion by inflammation-activated osteoclasts, and the limi-
tations in choices of treatment used to control arthritis
in this fragile population. As older patients are particu-
larly susceptible to joint damage in the presence of
elevated 14-3-3η and CRP, this combination of unfavor-
able biomarkers might be used to identify those patients
most likely to benefit from more targeted treatment
strategies.
Our study has numerous strengths. First we followed a
large number of patients over a 5-year period following
onset of disease. Second, the assessment of the patients
was exhaustive, including serial sera and SvH scores on
radiographs of the hands and feet. Third, the prospective
nature of our study allowed us to determine the relative
contribution of a number of baseline and early variables
to disease activity and radiographic progression observed
longitudinally. Fourth, our patients were treated-to-
target rapidly after symptom onset, similar to currently
recommended strategies. Fifth, our patients had minimal
missing data, and no imputations were done. Sixth, our
patients originate from a cohort of consecutive EPA pa-
tients, with minimal bias and variability of evaluation
and treatment. Nonetheless, the vast majority (>90 %)
already fulfilled classification criteria for RA at baseline.
Our study also has limitations. First, only those EPA
patients followed for 5 years were selected for this study.
Indeed, the selected patients were significantly younger
Table 5 Multivariate analysis of biomarkers and their interactions to predict radiographic and erosive progression
GLM ΔSvH estimate (SE) ΔErosion estimate (SE)
14-3-3η 0.098 (0.045) * 0.088 (0.033) **
Age (years) 0.106 (0.017) *** 0.056 (0.013) ***
Anti-CCP2 0.003 (0.002) 0.001 (0.002)
RF 0.000 (0.001) 0.000 (0.001)
Anti-Sa positive 3.104 (0.747) *** 2.878 (0.543) ***
CRP 0.032 (0.008) *** 0.025 (0.006) ***
GEE ΔSvH ≥5 RR (95 % CI) ΔErosion ≥5 RR (95 % CI)
14-3-3η ≥0.50 ng/ml 2.176 (1.193–3.970) * 2.276 (1.448–3.577) ***
Age ≥65 years 2.680 (1.859–3.864) *** 2.751 (1.760–4.301) ***
Anti-CCP2-positive 1.048 (0.696–1.577) 1.134 (0.635–2.025)
RF-positive 1.191 (0.739–1.921) 1.689 (1.042–2.738) *
Anti-Sa-positive 1.537 (0.708–3.335) 2.507 (1.348–4.659) **
CRP >8.0 mg/L 1.425 (1.112–1.826) ** 1.834 (1.304–2.578) ***
14-3-3η ≥0.50 * age ≥65 years 0.677 (0.396–1.156) Not included
14-3-3η ≥0.50 * RF-positive 0.724 (0.386–1.358) 0.552 (0.310–0.983) *
14-3-3η ≥0.50 * anti-Sa positive 0.898 (0.470–1.717) 0.400 (0.204–0.786) **
Age ≥65 * anti-CCP2 positive 0.899 (0.507–1.596) 0.692 (0.351–1.365)
Age ≥65 * anti-Sa positive 0.593 (0.345–1.017) Not included
RF-positive * anti-Sa positive 1.256 (0.607–2.597) Not included
Anti-CCP2-positive * anti-Sa positive Not included 0.856 (0.424–1.728)
Age, gender, 14-3-3η, C-reactive protein (CRP) and rheumatoid arthritis-associated rheumatoid factor (RF), antibodies against citrullinated peptides, second generation
(anti-CCP2) and anti-Sa antibodies, and all their interaction terms were included in multivariate generalized linear model (GLM) or general estimating equation (GEE)
analysis. Only the models with the lowest Akaike information criterion (AIC) or quasi-AIC are presented. *p <0.05, **p <0.01, ***p <0.001. SE standard error
ΔSvH progression in the total Sharp score modified by van der Heijde, ΔErosion progression in the erosion component of the Sharp score modified by van der
Heijde. Not includedvariable excluded from the final model
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(60 vs 64.5 years; p = 0.01), reported more pain at base-
line (mean visual analog scale 0-100 (VAS) score 59.0 vs
51.5; p = 0.007), and were more frequently RF-positive
(44.1 % vs 35.7 %. p = 0.02) and anti-CCP2-positive (40.0
% vs 30.7 %, p = 0.01) but not anti-Sa/citrullinated vimen-
tin positive (22.1 % vs 17.2 %, p = 0.112) than the other
patients from our cohort, but did not differ in any other
significant variable. These small differences are unlikely
to affect the applicability of our results to most EPA pa-
tients. Second, the treatment prescribed for patients was
not uniform but remained largely the same for patients
with similar disease activity, as it was selected to rapidly
attain a state of zero swollen joints, with minimal long-
term corticosteroids. This may better reflect current clin-
ical practice, however. Third, we used a higher threshold
than the upper normal limit recommended by the manu-
facturer of the assay (≥0.50 vs ≥0.19 ng/ml). Like higher
titers of antibodies, higher levels of 14-3-3η (≥0.50 ng/
ml) present better prognostic properties. The threshold
to be used should thus be determined by the context in
which the assay is performed: when screening EPA pa-
tients for referral, a level of ≥0.19 ng/ml might be used
[19]; for estimation of individual prognosis in order to
define each patient’s individual treatment strategy, a
threshold ≥0.50 ng/ml might be recommended. Fourth,
the optimal use of currently available biomarkers to pre-
dict poor outcomes will require a thorough examination
in multiple different cohorts. Fifth and most important,
we observed that positive 14-3-3η levels identified pa-
tients at higher risk of worse outcomes; it remains to be
determined whether using the results of the assay to re-
fine optimized treatment can prevent or delay the devel-
opment of poor outcomes.
Conclusion
Measuring serum levels of the 14-3-3η protein appears to
be a positive addition to guide early identification of EPA
patients in need of an urgent referral to rheumatologists.
Moreover, the presence of elevated levels of 14-3-3η protein
clearly identifies a subset of patients at baseline with a high
risk of clinically refractory disease and significant joint dam-
age over the next 5 years. In addition, the persistence of a
high level of 14-3-3η protein despite treatment identifies
patients at high risk of structural damage, even in patients
achieving SDAI remission. And finally, high CRP and
elevated 14-3-3η protein at baseline and under treatment
represent an adverse prognostic signature suggesting that a
majority of these patients will deteriorate significantly,
especially in older individuals. Corroboration of our results
in other cohorts with different genetic backgrounds and
treatment strategies will establish the role that measure-
ment of 14-3-3η protein will play in the diagnosis of RA
among EPA patients and in the development of a personal-
ized medicine approach in EPA.
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